Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [Y113] to Paxillin (HRP)
- Suitable for: WB, IHC-P
- Reacts with: Human
- Conjugation: HRP
Product nameAnti-Paxillin antibody [Y113] (HRP)
See all Paxillin primary antibodies
DescriptionRabbit monoclonal [Y113] to Paxillin (HRP)
Tested applicationsSuitable for: WB, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Cow, Dog
Synthetic peptide within Human Paxillin aa 1-100 (N terminal). The exact sequence is proprietary.
- WB: HeLa and RAW 264.7 whole cell lysate. IHC-P: FFPE Human Skin (Normal) tissue sections.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Dissociation constant (KD)KD = 4.17 x 10 -10 M Learn more about KD
Storage bufferpH: 7.40
Preservative: 0.1% 10% Proclin 300 Solution
Constituents: 30% Glycerol, 1% BSA, PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab197612 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/7500. Detects a band of approximately 70 kDa (predicted molecular weight: 68 kDa).|
|IHC-P||1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionCytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix (focal adhesion).
Sequence similaritiesBelongs to the paxillin family.
Contains 4 LIM zinc-binding domains.
modificationsPhosphorylated on tyrosine residues during integrin-mediated cell adhesion, embryonic development, fibroblast transformation and following stimulation of cells by mitogens.
Cellular localizationCytoplasm > cytoskeleton. Cell junction > focal adhesion.
- Information by UniProt
- FLJ16691 antibody
- FLJ23042 antibody
- Paired box protein Pax 1 antibody
IHC Image of Paxillin staining in a section of formalin-fixed paraffin-embedded normal human skin*, performed on a Leica BOND. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20mins. The section was then incubated with ab197612, 1/50 dilution, for 15 mins at room temperature. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.
*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre
All lanes : Anti-Paxillin antibody [Y113] (HRP) (ab197612) at 1/7500 dilution
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
Lane 2 : RAW 264.7 (Mouse leukaemic monocyte macrophage cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 68 kDa
Observed band size: 70 kDa why is the actual band size different from the predicted?
Exposure time: 8 minutes
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab197612 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.
ab197612 has not yet been referenced specifically in any publications.